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Diabetic nephropathy is a long-term complication of diabetic mellitus. Many experimental evidences suggest that persistent
hyperglycaemia generates intracellular reactive oxygen species (ROS) and upregulates transforming growth factor-b1 and
extracellular matrix expression in mesangial and tubular epithelial cells, which is involved of free radicals in the pathogenesis
ofdiabetes and moreimportantly inthe developmentof diabetic complications.Antioxidants eﬀectively inhibithigh-glucose-and
H2O2-induced transforminggrowth factor-b1 and ﬁbronectin upregulation, thus providing evidence that ROS play an important
role in high glucose-induced renal injury. The ﬂavonoid luteolin has been shown to possess direct antioxidant activity, therefore
we hypothesize that it may be useful in treatment of many chronic disease associated with oxidative stress, such as diabetic
nephropathy via its antioxidant properties. Our results suggested that protection against development of diabetic nephropathy by
luteolin treatment involved changes in superoxide dismutase (SOD) activity, the malondialdehyde (MDA) content and expression
of Heme Oxygenase-1 (HO-1) protein.
1.Introduction
Herbal medicines are naturally occurring, plant-derived
substances with minimal or no industrial processing that
havebeenusedtotreat illnesswithin localorregional healing
practices. For a long time, herbal medicines or their extracts
have been used to cure various diseases [1–3], because
plant products are frequently considered to be less toxic
and more free from side eﬀects than synthetic ones [4].
Luteolin, a plant-derived ﬂavonoid, has a variety of biolog-
ical activities including well-known anti-inﬂammatory [5],
antimutagenic, and antitumorigenic [6] properties. More-
over, it possesses direct antioxidant activity [7], which may
be useful in treatment of many chronic disease associated
with oxidative stress, such as cardiovascular diseases [8, 9],
liver diseases [10, 11], diabetes [12], and aging [13]. Glucose
uptake and utilisation by peripheral tissues, such as liver,
muscle, and fat, is crucial for maintaining normal blood
glucose level.
Many experimental evidences suggest the involvement of
free radicals in the pathogenesis of diabetes [14]a n dm o r e
importantly in the development of diabetic complications
[12, 15, 16]. Free radicals are capable of damaging cellular
molecules, DNA, proteins, and lipids leading to altered
cellular functions. Many recent studies reveal that antiox-
idants capable of neutralizing free radicals are eﬀective
in preventing experimentally induced diabetes in animal
models [17, 18] as well as reducing the severity of diabetic
complications [16].
Diabetic nephropathy is one of the most serious compli-
cations of diabetes and the most common cause of end-stage
renal failure. At present, diabetic kidney disease aﬀectsabout
15%–25% of type I diabetes patients [19] and 30%–40% of
patients with type II diabetes [20]. Diabetic nephropathy is
characterized by speciﬁc renal morphological and functional
alterations. ROS play an important role in high glucose-
induced renal injury [21, 22]. Flavonoids are abundant plant
phenolic compounds. More than 6000 have been identiﬁed
to date, and some have been shown to possess hypoglycemic
and antidiabetic activities [23]. There is no report on
luteolin relating to protective role on diabetic nephropa-
thy. Therefore, the present study was aimed at determining2 Evidence-Based Complementary and Alternative Medicine
the protective eﬀects of luteolin on diabetic nephropathy in
STZ-induced DM.
2.Methods
All experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Animals of the
Chinese National Institutes of Health. Forty male Sprague-
Dawley rats, weighing 180–220g, were procured from an
authorized ﬁrm in Nanjing, China. They were housed in
a standard animal facility under controlled environmental
conditionsatroom temperature 22 ±2◦Cand12-hourlight-
dark cycle and received a standard pellet diet and water
ad libitum. At the beginning of the experimental period,
rats were assigned randomly into four groups: the control
group given a standard chow diet, the control group given
a luteolindiet, thediabetic group givena standard chow diet,
and the diabetic group given a luteolin diet. Type I diabetes
was induced as described previously [24]. Brieﬂy, diabetes
mellitus was induced by a single intraperitoneal injection
of streptozotocin (STZ, 70mg/kg) dissolved in 0.1M citrate
buﬀer (pH 4.5) in male Sprague-Dawley rats. The control
group rats were treated with the same volume citrate buﬀer.
Diabetes was conﬁrmed at 48h after STZ injection by
measuring the glucose concentrations of peripheral blood
obtained from the tail vein (One Touch SureStep Meter,
LifeScan, Calif, USA). All animals had free access to food
and water. Diabetes was diagnosed by a sustained glucose
concentration >15mmol/L. After diabetes was conﬁrmed,
luteolin feeding was started at a dose of 200mg/kg dissolved
in distilled water using an intragastric tube. The rats were
anaesthetized with pentobarbital sodium and sacriﬁced eight
weeks after conﬁrming high blood glucose level. Blood
samples and kidney were collected for biochemical analyses.
A 24-h urine was collected on the day before the blood
sample and aliquots were taken.
2.1. Biochemical Analyses. Blood samples for the measure-
ment of blood chemistry were drawn into prechilled EDTA-
containing tubes and immediately placed on ice. Blood
samples were centrifuged at 2300g for separation of serums
and stored at −70◦C until assay. Serums were used for the
estimationofglucose,24-h urea protein,bloodurea nitrogen
(BUN), and creatinine as described previously [24, 25]. The
levels of serum triacylglycerol (TG), total cholesterol (TC),
high density lipoprotein (HDL), and low density lipoprotein
(LDL) were measured as previously described [26]. Lipids in
livers such as TC and TG were also estimated by the above-
mentioned methods.
3.AntioxidantMeasurement
Kidney homogenate (10%, w/v) was prepared with 0.1M
PBS and centrifuged at 12000g for 10min. The supernatant
was used to determine superoxide dismutase (SOD) activity
andMalondialdehyde(MDA)levelswithcommerciallyavail-
able kits (Nanjing Jiancheng Bioengineering Institute).
Table 1: Weight changes of the rats.
Initial (g) Final (g)
Control group 190.1 ± 9.5 386.1 ± 25.7 P<. 001
Control luteolin group 189.4 ± 10.2 383.9 ± 23.5 P<. 001
DM group 195.9 ± 11.0 169.6 ± 12.8 P<. 001
DM luteolin group 194.3 ± 13.0 201.3 ± 17.8
Table 2: Change of Blood glucose.
48h (mmol/L) 8 weeks (mmol/L)
Control group 5.06 ± 0.47 5.51 ± 0.82
Control luteolin group 4.98 ± 0.56 5.31 ± 0.83
DM group 22.25 ± 2.56 21.48 ± 2.28
DM luteolin group 21.73 ± 2.59 13.66 ± 1.84 P<. 01
3.1. Luteolin on Histology. At the end of followup, all
rats were euthanized with high-dose pentobarbital. The
kidneys were immediately removed and ﬁxed in 4% neutral
formalin for 2 hours. Three short-axis slices of renal tissue
w e r eo b t a i n e da n de m b e d d e di np a r a ﬃn. Sections were
c u ta t4 m mw i t ham i c r o t o m ea n dd e p a r a ﬃned with
xylene. They were stained with Hematoxylin-Eosin (H-E)
staining. Stained kidney sections were observed under a light
microscope at magniﬁcations of 400x.
3.2. Luteolin on Heme Oxygenase-1 and Phosphorylated Akt.
Kidney samples (0.2g) were lysed and homogenized in 2mL
of lysis buﬀer (10mM Tris-buﬀered saline, 1mM EDTA,
1mMEGT A,2mMsodiumorthovanadate,0.2mMPMSF ,
2μg/mL leupeptin, 2μg/mL aprotinin, and 1% Triton X-
100) for 30min on ice and cleared by centrifugation at
13,000g for 15min at 4◦C. Total protein concentration was
determinedinthesupernatantusingtheBradfordassay (Bio-
Rad Laboratories, Hercules, Calif, USA).Foreach lane, equal
amounts of protein were mixed with sodium dodecyl sulfate
(SDS) sample buﬀer and boiled for 5 minutes. Samples were
separated on a 10% sodium dodecyl sulfatepolyacrylamide
gel and then transferred to 0.2-μm nitrocellulose membrane.
Nitrocellulose blots were blocked by incubation in TBST
(10mM Tris-HCl, pH 7.5, 150mM NaCl, and 0.1% Tween
20) containing 5% nonfat milk for 1h at room temperature
and then incubated with a rabbit polyclonal anti-Heme
oxygenase-1 (HO-1), AKT/PKB, phospho-AKT/PKB, β-
actin antibody (1:500 dilution) overnight at 4◦C. After 3
washing steps, a secondary antirabbit antibody (1:10,000
dilution) was added and incubated for 1 hour. After rinsed
with wash buﬀer for three times, the reaction was visualized
by DAB.
3.2.1. Statistical Analysis. All values are expressed as mean
± s.e.m. Statistical evaluation was done using one way
analysisofvariance (ANOVA)followedbyDuncan’smultiple
range test (DMRT) by using SPSS 11.09 for windows. The
signiﬁcance level was set at P<. 05.Evidence-Based Complementary and Alternative Medicine 3
Table 3: Biochemical analysis in blood.
BUN (mmol/L) Creatinine (mmol/L) 24-h urea protein (mg)
Control group 4.67 ± 0.55 45.06 ± 4.49 4.38 ± 0.94
Control luteolin group 4.51 ± 0.47 43.83 ± 4.76 4.26 ± 0.63
DM group 14.59 ± 0.76∗∗ 89.15 ± 6.26∗∗ 36.41 ± 4.51∗∗
DM luteolin group 8.82 ± 0.80## 65.08 ± 5.32## 12.61 ± 2.54##
Values are expressed as mean ± SD of eight samples from each group. ∗∗P<. 01, signiﬁcantlydiﬀerent from control group and control luteolin group. ##P<
.01, signiﬁcantly diﬀerent from DM group.
Table 4: Change of serum lipids proﬁle.
Groups TC (mmol/L) TG (mmol/L) LDL (mmol/L) HDL (mmol/L)
Control group 1.53 ± 0.29 0.71 ± 0.14 2.02 ± 0.43 1.35 ± 0.23
Control luteolin group 1.48 ± 0.24 0.69 ± 0.13 2.12 ± 0.40 1.31 ± 0.25
DM group 5.60 ± 0.71∗∗ 2.65 ± 0.51∗∗ 7.04 ± 0.85∗∗ 0.41 ± 0.13∗∗
DM luteolin group 2.62 ± 0.35## 1.05 ± 0.14## 3.47 ± 0.58## 0.74 ± 0.17##
Values are expressed as mean ± SD of eight samples from each group. ∗∗P<. 01, signiﬁcantlydiﬀerent from control group and control luteolin group. ##P<
.01, signiﬁcantly diﬀerent from DM group.
4.Results
In this study, the STZ-treated diabetic rats developed
uncontrolled type 1 diabetes mellitus. Rats that had received
streptozotocinbecame diabeticatafrequencyof80%.Allthe
ratshad well-developedsignsofdiabetesafter2weeksofSTZ
administration, that is, hyperglycaemia, glycosuria, polyuria,
increased water consumption, and weight loss. Diabetes was
associated with reduced body weight when compared with
the control rats. Changes in initial and ﬁnal body weight
(BW) of normal control and experimental groups are shown
in Table 1. As expected, marked BW loss was observed
in diabetic rats. However, luteolin treatment appeared to
protect the diabetic rats from massive BW loss. Luteolin-
treated rats showed a recovery in ﬁnal BW which was close
to that of normal control rats.
4.1. Biochemical Finding. Blood glucose level was very high
in DM group and DM luteolin group in 48h after STZ
injection. After 8 weeks, treatment with luteolin showed
a signiﬁcant fall of blood glucose level in diabetic rats
(Table 2). BUN, serum creatinine, and 24-h urea protein
were measured, and the results are shown in Table 3.
The levels of BUN, 24h urea protein, and creatinine
were signiﬁcantly increased in STZ-induced diabetic rats
when compared with those of normal control rats treated
and untreated with luteolin. Administration of luteolin at
200mg/kg to diabetic rats tends to bring the values to near
normal. The levels of blood urea nitrogen, 24h urea protein,
and creatinine were signiﬁcantly decreased.
4.1.1. Serum and Tissue Lipids Proﬁle. Eﬀects of treatment
with luteolin to diabetic rats on serum lipids like TC, TG,
serum high density lipoprotein (HDL), and low-density
lipoprotein (LDL) are presented in Table 4.A sw a ss h o w n
in Table 4 that the levels of serum TC, TG, and LDL were
signiﬁcantly increased in diabetic rats when compared with
those of normal control rats, while the level of serum HDL
Table 5: Change of kidney lipids proﬁle.
TC (mg per g
protein)
TG (mg per g
protein)
Control group 5.74 ± 0.37 4.51 ± 0.34
Control luteolin group 5.68 ± 0.35 4.39 ± 0.35
DM group 10.90 ± 0.78∗∗ 10.68 ± 0.75∗∗
DM luteolin group 6.79 ± 0.69## 6.14 ± 0.48##
Values are expressed as mean ± SD of eight samples from each group.
∗∗P<. 01, signiﬁcantly diﬀerent from control group and control luteolin
group. ##P<. 01, signiﬁcantly diﬀerent from DM group.
was signiﬁcantly decreased in diabetic rats when compared
to that of normal control rats. The serum lipids like TC,
TG, and LDL were signiﬁcantly decreased and HDL was
signiﬁcantly increased in diabetic rats treated with luteolin
when compared with those of diabetic rats.
Furthermore, there were signiﬁcant increases of TC and
TG in kidney in STZ-induced diabetic rats when compared
to those of normal control rats. On the other hand, TC and
TG levels in kidney were signiﬁcantly decreased in diabetic
rats treated with luteolinwhen compared tothose ofdiabetic
rats (Table 5).
4.2. Antioxidant Eﬀects of Luteolin. As shown in Figure 1,
SOD activity was signiﬁcantly decreased and MDA level
signiﬁcantly increased in the kidney of STZ-induced diabetic
rats when compared with those in normal control rats.
Luteolin signiﬁcantly enhanced SOD activity and reduced
MDA level in kidney homogenates.
4.3.Histopathological Finding. Diabeticnephropathy ischar-
acterized by an expansion of glomerular mesangium, which
is caused by mesangial cell proliferation and excessive
accumulation of ECM [27]. As demonstrated in Figure 2,i n
the normal rats, the outer cortical glomerulus was of normal
size and conﬁguration. Moreover, the mesangium contained4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Changes of antioxidant eﬀects in the kidney of each group. (A) Control rat. (B) Control rat with luteolin. (C) Diabetic rat. (D)
Diabetic rats with luteolin. The kidney specimen of the diabetic group showed a markedly decrease of SOD activity and increase of MDA




Figure 2: Photomicrographs of H-E staining in the kidney of each
group. (a) Control rat. (b) Control rat with luteolin. (c) Diabetic
rat. (d) Diabetic rats with luteolin. The kidney specimen of the
diabetic group showed markedly severe destruction in glomerular
and tubulointerstitial lesions such as glomerular sclerosis atrophy,
interstitial expansion, and interstitial cellular inﬁltration (c). Gen-
eral morphology of glomerulus and tubulointerstitial lesions were
much improved and showed quite normalappearance.
the usual complement of cells and matrix without ECM
accumulation. The glomeruli from diabetic rat kidneys were
dramatically diﬀerent in appearance.
Western Blot. Ourdatashowasigniﬁcant increaseexpression
of HO-1 protein in diabetic rat kidneys compared with
that in the normal. Treatment with luteolin to diabetic
rats increased expression of HO-1 protein (Figure 3). We
also documented the fall of serine-473 phosphorylation of
AKT/PKB in diabetic rat kidneys compared to that in the
normal rat kidneys. Luteolin treatment increased AKT/PKB
phosphorylation in diabetic rat kidneys compared with that
in the untreated diabetic rat kidneys (Figure 3).
5.Discussion
In the presence study, we provide evidence that protection
against the development of diabetic nephropathy by luteolin
treatment involves changes in the expression of HO-1 and
p-Akt. Our results show that luteolin treatment prevented
the development of diabetic nephropathy by signiﬁcantly
lowering BUN and creatinine in diabetic animals. Luteolin-
fed rats had less renal injury. This could be explained that
there was increased clearance ofbloodurea and creatinine by
the kidney or that there was decreased protein degradation.
Moreover, luteolin also prevented the increase in 24-h urea
protein in diabetic rats.
Increased polyol pathway activity induced by hypergly-
caemiahasbeenreportedtocontributetoabnormalitiessuch
as increased osmotic and oxidative stress factors that have
been cited as promoters of diabetic microvascular diseases
including diabetic nephropathy [28]. High plasma MDA
level and decreased SOD activity are found in diabetes
[29]. Antioxidants (e.g., vitamins C and E) protect against
the development of diabetic nephropathy [30]. Various
biological actions of luteolin are mediated by inhibitingEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Western blot analysis in the kidney of each group. (A) Control rat. (B) Control rat with luteolin. (C) Diabetic rat. (D) Diabetic
rats with luteolin. The kidney specimen of the diabetic group showed markedly a elevated expression of HO-1 and decreased p-Akt (C).
∗∗P<. 01, signiﬁcantlydiﬀerent from control group and control luteolin group. ##P<. 01, signiﬁcantly diﬀerent from DM group.
oxidative stress [7] and inﬂammation [5]. Moreover, luteolin
has been reported to mediate its eﬀects by modulating
several important molecular targets, including transcrip-
tion factors (nuclear factor-kB and activating protein-1)
[31], enzymes (inducible nitric oxide synthase inhibitor)
[32], and cytokines (tumour necrosis factor-a, interleukin-
1, interleukin-6, and chemokines) [33]. In present study,
luteolin was found to decreased MDA level and increased
SOD activity in kidney homogenate.
The abnormal high concentration of serum lipids is
mainly due to increase in the mobilization of free fatty acids
from the peripheral fat deposits, because insulin inhibits the
hormone sensitive lipase production. Therefore, the elevated
level of serum lipids in DM causes the risk of diabetic
nephropathy [34, 35]. It has been well established that DM
alters the normal metabolism of tissues like kidney. The
administration of luteolin to diabetic rats tends to bring the
values to near normal. Luteolin is known to have antioxidant
properties [7], and this may reduce the susceptibility of
lipidstooxidationandstabilizethemembranelipids,thereby
reducing oxidative stress. However, administering luteolin
to diabetic rats tends to bring the values to near normal.
Thus, luteolin treatments exhibited hypocholesterolaemic,
hypotriglyceridaemic, and hypophospholipidaemic eﬀects
while at the same time increasing the HDL.
Increased plasma creatinine level and BUN are indica-
tions of the developmentof diabetic nephropathy in diabetic
rats [36, 37]. BUN and creatinine levels are higher in rats
with diabetic nephropathy than those in normal rats [38].
Maintenance ofthese biochemical variables closertothose in
control rats by luteolin treatment suggests that luteolin plays
a role, either directly or indirectly, in providing protection
against diabetic nephropathy or delay in its development.
Heme oxygenase-1 (HO-1), the inducible isoform of
the HO system, is a rate-limiting enzyme which converts
heme into equimolar amounts of iron, carbon monoxide,
and biliverdin. HO-1 is thought to have antioxidant and
cytoprotective roles [39]. The products of the HO reaction,
biliverdin, and carbon monoxide can be toxic at very high
concentrations. However, recent evidence indicates that they
are not toxic at physiological concentrations in normal
cells and that they may also have important antioxidant,
anti-inﬂammatory, or anti-apoptotic properties [40, 41].
AKT protein is a serine/threonine kinase and a downstream
eﬀector of PI3-K. It plays a crucial role in a variety of
cellular events such as apoptosis, cell cycle progression, and
transcriptional regulation [42]. The recent studies indicated
thatthe activated AKTaccountforthemodulation ofcardiac
function [43], and HO-1 may be induced by inﬂammation
and/or oxidative stress, which generates transcription factors6 Evidence-Based Complementary and Alternative Medicine
activated by p-AKT, then increased the level of HO-1
protein [44, 45]. Diabetes was associated with oxidative
stress; therefore, the level of HO-1 protein evelated. Our
results show that luteolin increases the level of HO-1
protein. These results suggest that one of the mechanism
of the renoprotective eﬀect of luteolin may be related to
increasing HO-1 expression and elevating antioxidant in
diabetic nephropathy.
In conclusion, the results from this study show that
luteolin may prevent morphological destruction of kidney
due to diabetes mellitus. Further studies are required to
determine the exact mechanism of the renoprotective eﬀect
of luteolin.
6.Conclusions
From the above results, it may be concluded that luteolin
may prevent the morphological destruction of the kidney
that is associated with diabetes mellitus and may improve
the redox balance in the kidney.Therefore, long-term control
of antioxidant levels using a luteolin diet may prevent the
progression of diabetes mellitus and prevent nephropathy.
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